Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Monday. The firm issued a sell rating on the stock.

Separately, Roth Mkm reiterated a buy rating and issued a $20.00 target price on shares of Bio-Path in a research note on Monday, July 8th.

Bio-Path Stock Performance

Shares of BPTH opened at $1.10 on Monday. The company’s fifty day moving average is $1.13 and its 200-day moving average is $2.06. Bio-Path has a 12 month low of $0.85 and a 12 month high of $21.60.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter last year, the business posted ($10.60) EPS. Analysts expect that Bio-Path will post -6.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is owned by institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.